Assenagon Asset Management
CRBP icon

Assenagon Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Assenagon Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-85,246
Closed -$800K – 1183
2026
Q1 		$800K Sell
85,246
-102,710
-55% -$865K ﹤0.01% 932
2025
Q4 		$1.53M Buy
187,956
+102,609
+120% +$1.27M ﹤0.01% 862
2025
Q3 		$1.08M Buy
+85,347
New +$812K ﹤0.01% 921
2024
Q4 		– Sell
-221,184
Closed -$4.56M – 1355
2024
Q3 		$4.56M Sell
221,184
-17,575
-7% -$899K 0.01% 743
2024
Q2 		$10.8M Sell
238,759
-20,697
-8% -$871K 0.02% 417
2024
Q1 		$10.2M Buy
+259,456
New +$6.4M 0.02% 423

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Assenagon Asset Management's CRBP Position: Q2 2026 in Review

Assenagon Asset Management sold out of Corbus Pharmaceuticals (CRBP) in Q2 2026, closing a stake of 85,246 shares — an estimated $800K sold.

Assenagon Asset Management first reported a position in CRBP in Q1 2024 and held it in 6 quarters. The position peaked at $10.8M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Assenagon Asset Management reported no remaining Corbus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Assenagon Asset Management sold 85,246 Corbus Pharmaceuticals shares in Q2 2026, an estimated $800K.
  • Assenagon Asset Management first reported a position in Corbus Pharmaceuticals in Q1 2024 and held it in 6 quarters.
  • Assenagon Asset Management's Corbus Pharmaceuticals position peaked at $10.8M in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.